Gritstone Bio has patented a method for designing a cassette sequence for a neoantigen vaccine. By utilizing a machine-learned presentation model, the method identifies therapeutic epitopes with high presentation likelihoods, minimizing the risk of junction epitopes being presented. This innovation aims to enhance the effectiveness of neoantigen vaccines. GlobalData’s report on Gritstone Bio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Gritstone Bio, Personalized cancer vaccines was a key innovation area identified from patents. Gritstone Bio's grant share as of February 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
Method of identifying cassette sequence for neoantigen vaccine
A recently granted patent (Publication Number: US11885815B2) outlines a method for identifying a cassette sequence for a neoantigen vaccine. The process involves obtaining data representing peptide sequences of neoantigens for a subject, which differ from wild-type sequences found in normal cells. This data is then input into a machine-learned presentation model to generate numerical presentation likelihoods for each neoantigen, indicating the likelihood of presentation by MHC alleles on tumor cells. A treatment subset of neoantigens is identified based on predetermined criteria, and a cassette sequence is determined by concatenating therapeutic epitopes from the treatment subset. The ordering of therapeutic epitopes in the cassette sequence is selected based on the presentation likelihoods of junction epitopes spanning adjacent pairs of therapeutic epitopes.
Furthermore, the patent details additional aspects of the method, such as the inclusion of junction epitopes overlapping with therapeutic epitopes and the use of linker sequences between therapeutic epitopes. The process involves determining distance metrics for ordered pairs of therapeutic epitopes, combining presentation likelihoods of junction epitopes, and calculating presentation scores for each ordered pair. These scores are then used to determine the overall presentation likelihood of the cassette sequence. The method also encompasses the manufacturing of a tumor vaccine containing the identified cassette sequence, highlighting the practical application of the innovative approach outlined in the patent.
To know more about GlobalData’s detailed insights on Gritstone Bio, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
